TScan Q3 net loss $29.9M; ALLOHA heme trial shows no relapses in 16 treatment patients

TScan Therapeutics, Inc.

2024-Q3 EPS reported -$0.84 revenue$2,151,000

Net loss $29.9M in Q3 2024 vs $23.0M in Q3 2023; revenue $1.0M vs $3.9M.
Cash $271.1M, excluding $5M restricted cash; funding operations into Q4 2026.
ALLOHA Phase 1 heme trial: 16/16 treatment-arm patients relapse-free and MRD-negative as of July 8 cutoff; 3/11 control-arm relapses.
On track to dose first patient with multiplex TCR-T therapy and provide Phase 1 update by end of 2024.
IND filing for MAGE-A4-targeted TCR-T (TSC-202-A0201) planned by end of year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.